Adam Koppel

Insider Reports History

Identity
Location
Boston, MA
SEC record
Signature
/s/ Adam Koppel
SEC evidence
Transaction view
Report rows are grouped by the transaction date disclosed in the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Holdings reported by Adam Koppel:

Form 4 holding Director, 10%+ Owner

Solid Biosciences Inc.

Security class
Common Stock
Shares / value
4,034,582
Estimated value
$22,311,238
Report date
11 Jan 2024
Price
$5.53
Ownership
Indirect
Form 4 holding Director

Foghorn Therapeutics Inc.

Security class
Stock Options (Right to buy)
Shares / value
16,000
Estimated value
$88,320
Report date
26 Jun 2024
Price
$5.52
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director, 10%+ Owner

Aptinyx Inc.

Security class
Stock Option (Right to Buy)
Shares / value
40,000
Estimated value
Report date
26 May 2022
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director, 10%+ Owner

Kailera Therapeutics, Inc.

Security class
Stock Option (right to buy)
Shares / value
38,300
Estimated value
Report date
16 Apr 2026
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director, 10%+ Owner

Solid Biosciences Inc.

Security class
Director Stock Option (Right to Buy)
Shares / value
9,650
Estimated value
Report date
06 Jun 2023
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director, 10%+ Owner

Cerevel Therapeutics Holdings, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
0
Estimated value
Report date
01 Aug 2024
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Dicerna Pharmaceuticals Inc

Security class
Director Stock Option (Right to Buy)
Shares / value
0
Estimated value
Report date
28 Dec 2021
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Dicerna Pharmaceuticals Inc

Security class
Restricted Stock Units
Shares / value
0
Estimated value
Report date
28 Dec 2021
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director, 10%+ Owner

Kailera Therapeutics, Inc.

Security class
Series A-1 Preferred Stock
Shares / value
0
Estimated value
Report date
20 Apr 2026
Price
Ownership
Indirect
Underlying class
Common Stock
Underlying amount
Form 4 holding Director, 10%+ Owner

Kailera Therapeutics, Inc.

Security class
Series B Preferred Stock
Shares / value
0
Estimated value
Report date
20 Apr 2026
Price
Ownership
Indirect
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Adam Koppel

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .